Tom Wilemon

William Blot, PhD, and his wife, Frances, deeded the proceeds of the sale of their home to VUMC after William Blot retired in April.
May 20, 2021

William and Frances Blot deed home to VUMC to benefit cancer patients

Their condominium in The Westbury was at the heart of all that William and Frances Blot loved about Nashville — its proximity to Vanderbilt where he worked for two decades, its sidewalk that led to the greenspaces where they would watch the seasons change, and its residents who became more like friends than neighbors.

By Tom Wilemon
May 13, 2021

People at high genetic risk for colorectal cancer benefit more from lifestyle changes

People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.

By Tom Wilemon
April 29, 2021

Grisanti receives VUMC Social Worker of the Year Award

Lindsay Grisanti, LMSW, is the recipient of the Carolyn Edwards Social Worker of the Year Award at Vanderbilt University Medical Center.

By Tom Wilemon
April 21, 2021

Zheng named VICC associate director for Population Sciences Research

Wei Zheng, MD, PhD, MPH, Anne Potter Wilson Professor of Medicine, has been named associate director for Population Sciences Research at Vanderbilt- Ingram Cancer Center (VICC).

By Tom Wilemon
April 15, 2021

Method proposed to correct misinterpretations of long-term survival rates for immunotherapies

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

By Tom Wilemon
April 6, 2021

Vanderbilt mourns the passing of Pierre Massion

Pierre Massion, MD, Cornelius Vanderbilt Chair and Professor of Medicine, an internationally known expert on early detection and prevention strategies for lung cancer, died April 4 of an apparent heart attack. He was 58.

By Tom Wilemon
March 26, 2021

Total skin electron therapy offered in Spring Hill

A radiation therapy device for the treatment of a rare cancer has been designed, custom built and installed at Vanderbilt-Ingram Cancer Center at Maury Regional Spring Hill, offering patients from Alabama, Mississippi, Georgia and southern Tennessee more convenient care.
By Tom Wilemon
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
By Tom Wilemon
March 18, 2021

Vanderbilt research played key role in new lung screen guidelines

The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
By Tom Wilemon
March 18, 2021

EGFR Resisters/LUNGevity fund lung cancer research

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.
By Tom Wilemon
March 9, 2021

Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.
By Tom Wilemon
February 25, 2021

Gift in memory of Phran Galante boosts lung cancer research

A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.
By Tom Wilemon